Bank of New York Mellon Corp Cuts Stake in Illumina, Inc. $ILMN

Bank of New York Mellon Corp lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,623,435 shares of the life sciences company’s stock after selling 57,611 shares during the period. Bank of New York Mellon Corp’s holdings in Illumina were worth $212,930,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the last quarter. HighPoint Advisor Group LLC grew its stake in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the last quarter. Assetmark Inc. grew its stake in shares of Illumina by 10.2% during the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Illumina by 4.2% during the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after acquiring an additional 99 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in shares of Illumina by 1.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 7,071 shares of the life sciences company’s stock worth $927,000 after acquiring an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 3.4%

Illumina stock opened at $162.32 on Friday. The stock has a market capitalization of $24.56 billion, a PE ratio of 29.51, a price-to-earnings-growth ratio of 3.15 and a beta of 1.50. Illumina, Inc. has a 12 month low of $82.44 and a 12 month high of $177.22. The business has a 50 day simple moving average of $137.75 and a 200-day simple moving average of $133.57. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business earned $0.97 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $98,400.00. Following the completion of the sale, the insider directly owned 21,568 shares in the company, valued at approximately $3,450,880. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,002,371 shares of company stock valued at $155,472,900 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ILMN shares. Piper Sandler decreased their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Canaccord Genuity Group decreased their target price on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group reaffirmed a “neutral” rating and set a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Finally, Guggenheim lifted their target price on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $138.38.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.